Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Nordin M. J. Hanssen*, Karin A. M. Jandeleit-Dahm

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)303-309
Number of pages7
JournalDiabetes & Vascular Disease Research
Volume16
Issue number4
DOIs
Publication statusPublished - Jul 2019

Keywords

  • Dipeptidyl peptidase-4 inhibitors
  • cardiovascular disease
  • type 2 diabetes
  • chronic kidney disease
  • clinical trials
  • OLDER PARTICIPANTS
  • HEART-FAILURE
  • DOUBLE-BLIND
  • OUTCOMES
  • SAFETY
  • SITAGLIPTIN
  • LINAGLIPTIN
  • SAXAGLIPTIN
  • PANCREATITIS
  • METAANALYSIS

Cite this